An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.

  • Bertram, Kelly (Primary Chief Investigator (PCI))
  • Fung, Victor S C (Chief Investigator (CI))
  • Hayes, Michael (Chief Investigator (CI))
  • Stell, Richard (Chief Investigator (CI))
  • Kimber, Thomas E (Chief Investigator (CI))
  • Bonke, Vicki (Project Manager)

Project: Research

Project Details

Effective start/end date6/10/2031/12/25


  • Neurodegenerative diseases
  • Parkinson's disease
  • Clinical trial